Biology subjects

Alzheimers Disease Neuroimaging Initiative,

Publications and source records attributed to Alzheimers Disease Neuroimaging Initiative,.

12 recordsLinked to original sources

bioRxiv2026

Calibration-Aware and Interpretable Graph Learning for Multi-Cohort Diffusion Connectome Brain-Age Modeling

Brain-age models derived from diffusion MRI-based structural connectomes may provide imaging biomarkers of accelerated brain aging, but their biological interpretation and transportability across heterogeneous populations remain uncertain. We developed a calibration-aware and hierarchically interpretable graph-learning framework and evaluated it across four independent aging and Alzheimer's disease-related cohorts: ADNI, Duke/UNC ADRC, HABS-HD, and AD-DECODE. The analysis included 1,093 connectome sessions from 789 participants. Cohort-specific graph neural networks were trained using participant-grouped cross-validation across five imaging and multimodal feature configurations. Prediction performance varied more strongly across cohorts than across feature sets, with imaging-only out-of-fold mean absolute error ranging from 4.72 years in ADNI to 9.75 years in AD-DECODE. The imaging-only graph neural network was competitive with ridge, elastic-net, and gradient-boosted regression models trained on matched vectorized connectome features, but was not uniformly superior. Age-bias-corrected brain-age gap was most consistently associated with reduced diffusion-derived microstructural integrity and structural-network organization across cohorts. In longitudinal analyses, corrected brain-age gap showed moderate-to-good within-person preservation in ADNI and HABS-HD, with intraclass correlation coefficients of 0.67 and 0.81, respectively; higher baseline values also predicted subsequent microstructural and network deterioration in ADNI. Multiscale SHAP analysis identified distributed contributions from global graph topology, regional imaging features, edge-derived regional summaries, and individual structural connections involving thalamic, striatal, frontal, parietal, cerebellar, hippocampal, and entorhinal circuitry. External transfer was highly sensitive to cohort shift: across 12 off-diagonal train-test evaluations, median mean absolute error decreased from 17.39 to 8.22 years after target-cohort linear recalibration, whereas median Pearson correlation remained 0.17. Because recalibration used target-cohort chronological age, it was interpreted as a diagnostic sensitivity analysis rather than deployable external validation. Together, these findings support calibration-aware diffusion-connectome brain age as an interpretable imaging biomarker of structural brain aging and prospective microstructural and network vulnerability, while emphasizing the need for cohort-specific calibration before external application.

neuroscience↗

bioRxiv2026

Automated Segmentation of Brainstem and Subcortical White Matter: Mapping the Deep Tegmental Core with BundleParc

Diffusion MRI enables noninvasive mapping of human white matter pathways, but automated segmentation methods have largely focused on large association, projection, and commissural bundles. Brainstem and subcortical pathways supporting basal ganglia, cerebellar, limbic/reward, sensory, and homeostatic functions remain underrepresented in large-scale connectomic analyses. To address this gap, we adapted BundleParc, a recently introduced bundle-parcellation architecture, into an automated pipeline for direct segmentation and along-tract parcellation of 97 subcortical and brainstem white matter pathways. The model was trained on a curated reference dataset derived from Human Connectome Project diffusion MRI using anatomy-guided tractography, explicit inclusion and exclusion criteria, automated outlier filtering, and manual quality assurance. Operating directly on native-space fiber orientation distributions, the algorithm successfully recovers these intricate anatomical trajectories and ordered parcellations. We show the model generalizes to diverse external datasets spanning development, aging, and neurodegenerative disease cohorts, maintaining robust performance across variations in spatial resolution and angular sampling. The released container, trained model, population atlas, reference streamlines, and quality assurance outputs provide a resource for studying deep brainstem and subcortical pathways in development, aging, disease, and neuromodulation-relevant anatomy.

neuroscience↗

bioRxiv2026

Reproducible Tools and Enhanced Computational Workflows for Batch Effect Evaluation of High-Throughput Data Using BatchQC

Batch effect correction is a common and often necessary step in data analysis to reduce bias due to technical and experimental factors when combining multiple batches of data. The severity of the batch effects dictates the correction strategy; therefore, a careful assessment of each datasets batch effects is necessary. BatchQC is an R package that provides reproducible tools and visualizations for quantitatively and qualitatively addressing batch effects across a broad range of data types. BatchQC integrates with standardized Bioconductor data structures and features an object-oriented design, enabling the application of workflows that can freely evaluate and process data within and outside the package tools. Common batch evaluation methods, along with novel quantitative metrics, help determine the benefits of batch correction for each dataset and enable direct comparisons between methods. Here, we present BatchQC as the first comprehensive batch-correction R package, with independent tools, reproducible workflows, visualization, and novel statistics.

bioinformatics↗

bioRxiv2026

Analytic Bounds on GAMLSS Model Variability of Normative White Matter Brain Charts

Brain charts, or normative models of quantitative neuroimaging measures, can identify trajectories of brain development and abnormalities in groups and individuals by leveraging large populations. Recent work has extended these brain charts to model microstructural and macrostructural features of white matter. Assessments of variance for these brain charts are necessary to determine whether the models being used for these data are stable. We implement an analytic approach to characterize variability of the parameters in previously released brain charts created using the generalized additive models for location, scale, and shape (GAMLSS) framework. Additionally, we empirically validate the accuracy of each analytic model through a comparison to a bootstrapping approach from 0.2 to 90 years of age. We find that across all models, the analytic coefficient of variation (COV) remains below 5% for ages greater than 0.25 years, with the maximum empirical observed COV reaching 7% at 0.2 years of age. Further, the empirical assessment shows high agreement with the analytic assessment, with COV estimates averaged across the lifespan for all models having a Pearson correlation coefficient of 0.776 and a mean difference of 4 x 10-4. Both methods exhibit volume and surface area as the features with the largest average COV for the majority of tracts. However, the analytic assessment yields axial diffusivity as the feature most frequently having the smallest COV, whereas the corresponding feature for the empirical assessment is average length. These results suggest that the analytic approach overestimates model stability for WM brain charts when the COV is low and that the validation method is suitable for assessing whether GAMLSS models are unstable.

bioengineering↗

bioRxiv2025

White matter microstructure and macrostructure brain charts across the human lifespan

Normative reference charts are widely used in healthcare, especially for assessing the development of individuals by benchmarking anatomic and physiological features against population trajectories across the lifespan. Recent work has extended this concept to gray matter morphology in the brain, but no such reference framework currently exists for white matter (WM) even though WM constitutes the essential substrate for neuronal communication and large-scale network integration. Here, we present the first comprehensive WM brain charts, which describe how microstructural and macrostructural features of WM evolve across the lifespan, by leveraging over 35,120 diffusion MRI scans from 50 harmonized studies. Using generalized additive models for location, scale, and shape (GAMLSS), we estimate age- and sex-stratified trajectories for 72 individual white matter pathways, quantifying both tract-specific microstructural and morphometric features. We demonstrate that these WM brain charts enable four important applications: (1) defining normative trajectories of WM maturation and decline across distinct pathways, (2) identifying previously uncharacterized developmental milestones and spatial gradients of tract maturation, (3) detecting individualized deviations from normative patterns with clinical relevance across multiple neurological disorders, and (4) facilitating standardized, cross-study centile scoring of new datasets. By establishing a unified, interpretable reference framework for WM structure, these brain charts provide a foundational metric for research and clinical neuroscience. The accompanying open-access trajectories, centile scoring tools, and harmonization methods facilitate precise mapping of WM development, aging, and pathology across diverse populations. We release the brain charts and provide an out-of-sample alignment process as a Docker image: https://zenodo.org/records/17561821.

neuroscience↗

bioRxiv2024

WMH-DualTasker: A Dual-Task Deep Learning Model with Self-supervised Consistency for Automated Segmentation and Visual Rating of White matter Hyperintensities - a Multicentre study

BackgroundWhite matter hyperintensities (WMH) are neuroimaging markers linked to an elevated risk of cognitive decline. WMH severity is typically assessed via visual rating scales and through volumetric segmentation. While visual rating scales are commonly used in clinical practice, they offer limited descriptive power. In contrast, supervised volumetric segmentation requires manually annotated masks, which is labor-intensive and challenging to scale for large studies. Therefore, our goal was to develop an automated deep learning model that can provide accurate and holistic quantification of WMH severity with minimal supervision. MethodsWe developed WMH-DualTasker, a deep learning model that simultaneously performs voxel-wise segmentation and visual rating score prediction. The model employs self-supervised learning with transformation-invariant consistency constraints, using WMH visual ratings (ARWMC scale, range 0-30) from clinical settings as the sole supervisory signal. Additionally, we assessed its clinical utility by applying it to identify individuals with mild cognitive impairment (MCI) and to predict dementia conversion. FindingsThe volumetric quantification performance of WMH-DualTasker was either superior to or on par with existing supervised methods, as demonstrated on the MICCAI-WMH dataset (N=60, Dice=0.602) and the SINGER dataset (N=64, Dice=0.608). Furthermore, the model exhibited strong agreement with clinical visual rating scales on an external dataset (SINGER, MAE=1.880, K=0.77). Importantly, WMH severity metrics derived from WMH-DualTasker improved predictive performance beyond conventional clinical features for MCI classification (AUC=0.718, p<0.001), MCI conversion prediction (AUC=0.652, p<0.001) using the ADNI dataset. InterpretationsWMH-DualTasker substantially reduces the reliance on labor-intensive manual annotations, facilitating more efficient and scalable quantification of WMH severity in large-scale population studies. This innovative approach has the potential to advance preventive and precision medicine by enhancing the assessment and management of vascular cognitive impairment associated with WMH. Code and model weights are publicly available at https://github.com/hzlab/WMH-DualTasker.

neuroscience↗

bioRxiv2023

Study design features that improve effect sizes in cross-sectional and longitudinal brain-wide association studies

Brain-wide association studies (BWAS) are a fundamental tool in discovering brain-behavior associations. Several recent studies showed that thousands of study participants are required for good replicability of BWAS because the standardized effect sizes (ESs) are much smaller than the reported standardized ESs in smaller studies. Here, we perform analyses and meta-analyses of a robust effect size index using 63 longitudinal and cross-sectional magnetic resonance imaging studies from the Lifespan Brain Chart Consortium (77,695 total scans) to demonstrate that optimizing study design is critical for increasing standardized ESs and replicability in BWAS. A meta-analysis of brain volume associations with age indicates that BWAS with larger variability in covariate have larger reported standardized ES. In addition, the longitudinal studies we examined reported systematically larger standardized ES than cross-sectional studies. Analyzing age effects on global and regional brain measures from the United Kingdom Biobank and the Alzheimers Disease Neuroimaging Initiative, we show that modifying longitudinal study design through sampling schemes improves the standardized ESs and replicability. Sampling schemes that improve standardized ESs and replicability include increasing between-subject age variability in the sample and adding a single additional longitudinal measurement per subject. To ensure that our results are generalizable, we further evaluate these longitudinal sampling schemes on cognitive, psychopathology, and demographic associations with structural and functional brain outcome measures in the Adolescent Brain and Cognitive Development dataset. We demonstrate that commonly used longitudinal models can, counterintuitively, reduce standardized ESs and replicability. The benefit of conducting longitudinal studies depends on the strengths of the between-versus within-subject associations of the brain and non-brain measures. Explicitly modeling between-versus within-subject effects avoids averaging the effects and allows optimizing the standardized ESs for each separately. Together, these results provide guidance for study designs that improve the replicability of BWAS.

neuroscience↗

bioRxiv2019

Predicting Alzheimer’s disease progression trajectory and clinical subtypes using machine learning

BackgroundAlzheimers disease (AD) is a common, age-related, neurodegenerative disease that impairs a persons ability to perform day-to-day activities. Diagnosing AD is challenging, especially in the early stages. Many patients still go undiagnosed, partly due to the complex heterogeneity in disease progression. This highlights a need for early prediction of the disease course to assist its treatment and tailor therapy options to the disease progression rate. Recent developments in machine learning techniques provide the potential to not only predict disease progression and trajectory of AD but also to classify the disease into different etiological subtypes. Methods and findingsThe work shown here clusters participants in distinct and multifaceted progression subgroups of AD and discusses an approach to predict the progression rate from baseline diagnosis. We observed that the myriad of clinically reported symptoms summarized in the proposed AD progression space corresponds directly with memory and cognitive measures, which are routinely used to monitor disease onset and progression. Our analysis demonstrated accurate prediction of disease progression after four years from the first 12 months of post-diagnosis clinical data (Area Under the Curve of 0.96 (95% confidence interval (CI), 0.92-1.0), 0.81 (95% CI, 0.74-0.88) and 0.98 (95% CI, 0.96-1.0) for slow, moderate and fast progression rate patients respectively). Further, we explored the long short-term memory (LSTM) neural networks to predict the trajectory of an individual patients progression. ConclusionThe machine learning techniques presented in this study may assist providers in identifying different progression rates and trajectories in the early stages of the disease, hence allowing for more efficient and personalized healthcare deliveries. With additional information about the progression rate of AD at hand, providers may further individualize the treatment plans. The predictive tests discussed in this study not only allow for early AD diagnosis but also facilitate the characterization of distinct AD subtypes relating to trajectories of disease progression. These findings are a crucial step forward for early disease detection. These models can be used to design improved clinical trials for AD research.

neuroscience↗

bioRxiv2019

Decoding brain functional connectivity implicated in AD and MCI

Deep neural networks have been demonstrated to extract high level features from neuroimaging data when classifying brain states. Identifying salient features characterizing brain states further refines the focus of clinicians and allows design of better diagnostic systems. We demonstrate this while performing classification of resting-state functional magnetic resonance imaging (fMRI) scans of patients suffering from Alzheimers Disease (AD) and Mild Cognitive Impairment (MCI), and Cognitively Normal (CN) subjects from the Alzheimers Disease Neuroimaging Initiative (ADNI). We use a 5-layer feed-forward deep neural network (DNN) to derive relevance scores of input features and show that an empirically selected subset of features improves accuracy scores for patient classification. The common distinctive salient brain regions were in the uncus and medial temporal lobe which closely correspond with previous studies. The proposed methods have cross-modal applications with several neuropsychiatric disorders.

neuroscience↗

bioRxiv2019

The Alzheimer’s Disease Metabolome: Effects of Sex and APOE ε4 genotype

Recent studies have provided evidence that late-onset Alzheimers disease (AD) can in part be considered a metabolic disease. Besides age, female sex and APOE {varepsilon}4 genotype represent strong risk factors for AD. They also both give rise to large metabolic differences, suggesting that metabolic aspects of AD pathogenesis may differ between males and females and between APOE {varepsilon}4 carriers and non-carriers. We systematically investigated group-specific metabolic alterations by conducting stratified association analyses of 140 metabolites measured in serum samples of 1,517 AD neuroimaging initiative subjects, with AD biomarkers for A{beta} and tau pathology and neurodegeneration. We observed substantial sex differences in effects of 15 metabolites on AD biomarkers with partially overlapping differences for APOE {varepsilon}4 status groups. These metabolites highlighted several group-specific alterations not observed in unstratified analyses using sex and APOE {varepsilon}4 as covariates. Combined stratification by both variables uncovered further subgroup-specific metabolic effects limited to the group with presumably the highest AD risk: APOE {varepsilon}4+ females. Pathways linked to the observed metabolic alterations suggest that females experience more expressed impairment of mitochondrial energy production in AD than males. These findings indicate that dissecting metabolic heterogeneity in AD pathogenesis may enable grading of the biomedical relevance of specific pathways for specific subgroups. Extending our approach beyond simple one- or two-fold stratification may thus guide the way to personalized medicine.\n\nSignificance statementResearch provides substantial evidence that late-onset Alzheimers disease (AD) is a metabolic disease. Besides age, female sex and APOE{varepsilon}4 genotype represent strong risk factors for AD, and at the same time give rise to large metabolic differences. Our systematic investigation of sex and APOE {varepsilon}4 genotype differences in the link between metabolism and measures of pre-symptomatic AD using stratified analysis revealed several group-specific metabolic alterations that were not observed without sex and genotype stratification of the same cohort. Pathways linked to the observed metabolic alterations suggest females are more affected by impairment of mitochondrial energy production in AD than males, highlighting the importance of tailored treatment approaches towards a precision medicine approach.

bioinformatics↗

bioRxiv2018

Altered Bile Acid Profile in Mild Cognitive Impairment and Alzheimer’s Disease: Relationship to Neuroimaging and CSF Biomarkers

IntroductionBile acids (BAs) are the end products of cholesterol metabolism produced by human and gut microbiome co-metabolism. Recent evidence suggests gut microbiota influence pathological features of Alzheimers disease (AD) including neuroinflammation and amyloid-{beta} deposition.\n\nMethodSerum levels of 20 primary and secondary BA metabolites from the AD Neuroimaging Initiative (n=1562) were measured using targeted metabolomic profiling. We assessed the association of BAs with the \"A/T/N\" (Amyloid, Tau and Neurodegeneration) biomarkers for AD: CSF biomarkers, atrophy (MRI), and brain glucose metabolism ([18F]FDG-PET).\n\nResultsOf 23 BA and relevant calculated ratios, three BA signatures were associated with CSF A{beta}1-42 (\"A\") and three with CSF p-tau181 (\"T\") (corrected p<0.05). Furthermore, three, twelve, and fourteen BA signatures were associated with CSF t-tau, glucose metabolism, and atrophy (\"N\"), respectively (corrected p<0.05).\n\nConclusionThis is the first study to show serum-based BA metabolites are associated with \"A/T/N\" AD biomarkers, providing further support for a role of BA pathways in AD pathophysiology. Prospective clinical observations and validation in model systems are needed to assess causality and specific mechanisms underlying this association.

neuroscience↗

bioRxiv2018

Altered Bile Acid Profile Associates with Cognitive Impairment in Alzheimer’s Disease – An Emerging Role for Gut Microbiome

IntroductionIncreasing evidence suggests a role for the gut microbiome in central nervous system disorders and specific role for the gut-brain axis in neurodegeneration. Bile acids (BA), products of cholesterol metabolism and clearance, are produced in the liver and are further metabolized by gut bacteria. They have major regulatory and signaling functions and seem dysregulated in Alzheimer disease (AD).\n\nMethodsSerum levels of 15 primary and secondary BAs and their conjugated forms were measured in 1,464 subjects including 370 cognitively normal older adults (CN), 284 with early mild cognitive impairment (MCI), 505 with late MCI, and 305 AD cases enrolled in the AD Neuroimaging Initiative. We assessed associations of BA profiles including selected ratios with diagnosis, cognition, and AD-related genetic variants, adjusting for cofounders and multiple testing.\n\nResultsIn AD compared to CN, we observed significantly lower serum concentrations of a primary BA (cholic acid CA) and increased levels of the bacterially produced, secondary BA, deoxycholic acid (DCA), and its glycine and taurine conjugated forms. An increased ratio of DCA:CA, which reflects 7-dehydroxylation of CA by gut bacteria, strongly associated with cognitive decline, a finding replicated in serum and brain samples in the Rush Religious Orders and Memory and Aging Project. Several genetic variants in immune response related genes implicated in AD showed associations with BA profiles.\n\nConclusionWe report for the first time an association between altered BA profile, genetic variants implicated in AD and cognitive changes in disease using a large multicenter study. These findings warrant further investigation of gut dysbiosis and possible role of gut liver brain axis in the pathogenesis of AD.

neuroscience↗